PBAC's latest decision on Morphine hydrochloride: Recommended (2016). Considered for Relief of moderate to severe pain not responsive to non-opioid analgesics, symptomatic relief of severe and intractable pains in terminal cancer patients, and as a pre-operative medication and analgesic adjunct in general anaesthesia.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Patients requiring relief of moderate to severe pain not responsive to non-opioid analgesics, severe and intractable pain in terminal cancer patients, and perioperative analgesia.
Therapy area
Pain
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
morphine sulfate and morphine tartrate
Economic model
Cost-minimisation
ICER note
Minor submission with no economic comparison; cost-neutral on a price per mg basis.